Mitsubishi Tanabe Pharma Group receives import and marketing permission in Taiwan for CANAGLU® Tablets 100mg, a treatment agent for type 2 diabetes mellitus

Mitsubishi Tanabe Pharma Corporation (Head Office: Osaka; President & Representative Director: Masayuki Mitsuka) announced today that consolidated subsidiary Tai Tien Pharmaceuticals Co., Ltd. (Head Office: Taipei, Taiwan; General Manager: Hitoshi Kawabe) has received import and marketing permission for CANAGLU® Tablets 100mg (generic name: canagliflozin) for an indication of type 2 diabetes mellitus.

CANAGLU®, which was discovered in Japan by Mitsubishi Tanabe Pharma, inhibits sodium glucose co-transporter 2 (SGLT2), a transporter involved in the reabsorption of glucose in the proximal renal tubules of the kidneys; suppresses the reabsorption of glucose; and promotes the excretion of excessive glucose into the urine, and as a result, lowers blood glucose.

The number of diabetes patients in Taiwan has been increasing in recent years, and that trend is expected to continue.

Through licensees, CANAGLU® has been approved in more than 70 countries around the world. Following Japan, Taiwan will be the second market in which CANAGLU® is sold by the Mitsubishi Tanabe Pharma Group.

Tai Tien Pharmaceuticals, which was established in 1987, has marketed such products as HERBESSER®, CONCOR® (Japan name: MAINTATE®), and LIVALO®. Through the marketing of these products, Tai Tien Pharmaceuticals has built a foundation in the field of lifestyle diseases. Leveraging that foundation, the Group will provide CANAGLU® to patients with type 2 diabetes mellitus.

Moving forward, Mitsubishi Tanabe Pharma will continue working to implement business activities that facilitate the rapid delivery of better drugs to patients around the world more quickly.

〈〈For Details, Contact the Following Section〉〉

Corporate Communications Department
Tel +81-6-6205-5211